Non transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: Kinetics of its appearance and potential predictive role in infectious complications

Leukemia Research

Volumn 39, Issue 1, 2015, Pages 88-91

  Belotti, Angelo ^a   Duca, Lorena ^b   Borin, Lorenza ^a   Realini, Silvia ^a   Renso, Rossella ^a   Parma, Matteo ^a   Pioltelli, Pietro ^a   Pogliani, Enrico ^a   Cappellini, Maria Domenica ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute leukemia; Chemotherapy; Non transferrin bound iron; NTBI; Transfusional iron overload

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; FLUDARABINE; IDARUBICIN; IRON BINDING PROTEIN; MITOXANTRONE; NON TRANSFERRIN BOUND IRON; PREDNISOLONE; PREDNISONE; TRANSFERRIN; UNCLASSIFIED DRUG; VINCRISTINE; IRON;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; BONE MARROW; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; ERYTHROPOIESIS; FEMALE; GRAM NEGATIVE SEPSIS; HEMATOLOGICAL PARAMETERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RISK; INFECTIOUS COMPLICATION; IRON INTAKE; MALE; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RISK ASSESSMENT; TRANSFERRIN SATURATION; BLOOD; BONE MARROW CELL; CLINICAL TRIAL; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; LEUKEMIA, MYELOID, ACUTE; LIVER CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS;

ADULT; AGED; BONE MARROW CELLS; ERYTHROPOIESIS; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEPATOCYTES; HUMANS; IRON; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; TRANSFERRIN;

EID: 84920364574     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.11.003     Document Type: Article

References (13)

1. Pullarkat V. Iron overload in patients undergoing hematopoietic stem cell transplantation. Adv Hematol 2010, 2010:345-756.
2. Evens A.M., Mehta J., Gordon L.I. Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant 2004, 34:561-571.
3. Bradley S.J., Gosriwitana I., Srichairatanakool S., Hider R.C., Porter J.B. Non-transferrin-bound iron induced by myeloablative chemotherapy. Br J Haematol 1997, 99:337-343.
4. Sahlstedt L., von Bonsdorff L., Ebeling F., Parkkinen J., Juvonen E., Ruutu T. Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation. Eur J Haematol 2009, 83:455-459.
5. Harrison P., Marwah S.S., Hughes R.T., Bareford D. Non-transferrin bound iron and neutropenia after cytotoxic chemotherapy. J Clin Pathol 1994, 47:350-352.
6. Döhner H., Estey E.H., Amadori S., Appelbaum F.R., Büchner T., Burnett A.K., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
7. Bassan R., Spinelli O., Oldani E., Intermesoli T., Tosi M., Peruta B., et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009, 113:4153-4162.
8. Cohen A.R., Glimm E., Porter J.B. Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood 2008, 111:583-587.
9. Cappellini M.D., Porter J., El-Beshlawy A., Li C.K., Seymour J.F., Elalfy M., et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010, 95:557-566.
10. Porter J.B., Abeysinghe R.D., Marshall L., Hider R.C., Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996, 88:705-713.
11. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
12. Bullen J.J., Rogers H.J., Spalding P.B., Ward C.G. Iron and infection: the heart of the matter. Immunol Med Microbiol 2005, 43:325-330.
13. Kennedy G.A., Morris K.L., Subramonpillai E., Curley C., Butler J., Durrant S. A prospective phase II randomized study of deferasirox to prevent iatrogenic iron overload in patients undertaking induction/consolidation chemotherapy for acute myeloid leukaemia. Br J Haematol 2013, 161:794-801.